Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors.
about
Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseasesThe Melanocortin Receptor System: A Target for Multiple Degenerative DiseasesRetinal conformation governs pKa of protonated Schiff base in rhodopsin activationOptimization of time-resolved fluorescence assay for detection of europium-tetraazacyclododecyltetraacetic acid-labeled ligand-receptor interactions.Synthesis and characterization of a Eu-DTPA-PEGO-MSH(4) derivative for evaluation of binding of multivalent molecules to melanocortin receptors.Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cellsA sucrose-derived scaffold for multimerization of bioactive peptidesA solanesol-derived scaffold for multimerization of bioactive peptidesDevelopment of homomultimers and heteromultimers of lung cancer-specific peptoids.Heterobivalent ligands target cell-surface receptor combinations in vivo.An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.Organic chemistry and biology: chemical biology through the eyes of collaboration.The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivoA new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging.Fluorescent and lanthanide labeling for ligand screens, assays, and imaging.Development of a large peptoid-DOTA combinatorial library.Cell-specific targeting by heterobivalent ligands.Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: tools toward melanoma diagnosis and treatment.Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering.Peptide heterodimers for molecular imaging.Enhanced targeting with heterobivalent ligandsSolid-Phase Synthesis of Heterobivalent Ligands Targeted to Melanocortin and Cholecystokinin Receptors.Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.Peptide-based imaging agents for cancer detection.Adventures in peptides and science with students! The joys of research.Synthetic receptors with antibody-like binding affinities.Platforms for the identification of GPCR targets, and of orthosteric and allosteric modulators.Radiolabeled peptide-receptor ligands in tumor imaging.Radiolabeled heterobivalent peptidic ligands: an approach with high future potential for in vivo imaging and therapy of malignant diseases.Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer.Peptide-Decorated Dendrimers and Their Bioapplications.Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.Potent agonists of the protease activated receptor 2 (PAR2).Neuroligin 2 regulates spinal GABAergic plasticity in hyperalgesic priming, a model of the transition from acute to chronic painDevelopment of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells.A unique mid-sequence linker used to multimerize the lipid-phosphatidylserine (PS) binding peptide-peptoid hybrid PPS1.Iodine 125-labeled mesenchymal-epithelial transition factor binding peptide-click-cRGDyk heterodimer for glioma imaging.Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y₁)- and GRP-Receptors-An Improvement for Breast Cancer Imaging?
P2860
Q27025187-A5AD99C0-FF14-46E8-9377-ED8C79739766Q28273671-1CD26D05-79C0-454F-A0CC-8411612A8945Q28818812-AD1167DA-7D2D-4F45-B78B-F75728D2AA0BQ33512151-B0A8EF3A-D556-4BCD-9213-433BD1C02083Q33803703-BE4A5491-CAE3-4E82-9A5A-757A268B9826Q33804178-3CB2BE02-EFCF-438B-8C50-A47691BF1579Q34028115-AA0E1E9F-5B06-46EB-8ECC-1E8EF539C141Q34088316-5186F679-EDB2-478F-98A4-7D89FCB09FC8Q34105317-E22DE9BC-32A3-4DAB-9302-ED91422C9AE0Q34317386-0507BB12-315E-491D-87B9-DB809994AD6FQ34517465-266356CE-64AD-4B65-B6DA-D2FFB0D9643FQ34583191-81B446AA-1468-440E-9799-62B04181B84FQ34998283-3870D856-0B6F-4DBA-8883-83E31F47E788Q35009658-B51216A6-AC2C-43FB-B503-2328D1BCBD0EQ36003339-25118008-04CC-4341-9EC9-866662D82723Q36039518-5B7A0EEF-B914-41F2-9D94-5A336C880D4EQ36055049-D4F5A0E8-325E-46A6-B5AD-587FFA1FDFA9Q36464806-D2E3E6DE-D345-4B49-822F-6F73E9302D7DQ36710897-D2FF320D-F1E9-43A1-B482-6647D553D8DFQ36746620-7DE19C67-57A9-47AA-BCB3-AC959472F23FQ36870878-36E9C4D3-B680-41DC-84D5-366E577470F5Q37318781-C38AEB56-7382-48E2-A4B9-CEEE3B893582Q37365405-77D9D3B6-16DF-4DE2-A1FF-C0A071E46F22Q37389360-A2A28504-02B7-4E14-BB24-A95C31A21901Q37585965-C4328B34-D39F-4AFF-A400-9D6E8CB067F9Q37668565-2AD75AB3-AAB4-419A-98DD-8A87A1CA9BDFQ37776862-E486891C-0C04-411B-A653-ED385E99B9F4Q38028542-8762D749-3FC0-4E40-A510-8E32BF5B6290Q38088748-218AB50B-94CE-41EB-A69F-446DBFA2C601Q38096994-E1D8204F-3EA5-46E7-A77C-7492A95F3E5BQ38287805-C760826A-6992-4308-8EBD-154010489E5FQ38779839-81609C70-B151-49E9-B4A6-E55EAE2759DBQ39211934-08D0B3E4-1DBE-446C-9256-81E6E0296468Q39597862-0E2B719C-F423-4AC0-8186-332568B875C8Q42541482-BF9717FE-F09F-4E1E-AD30-18B89D250F4FQ42583795-4C960159-A8F0-475C-8D80-4274C1EEE127Q42737891-4B7CEF99-D866-4435-ADBA-58F8B422726AQ48791049-17F9CEC9-2223-4D39-833E-8B9473BD8AD9Q53224886-1DAB9871-E92D-4764-89FE-C4DA34FE3627Q57757457-7F8D1E1E-B3C4-4599-93A7-63F6A49C5C47
P2860
Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Heterobivalent ligands crossli ...... -4 and delta-opioid receptors.
@en
Heterobivalent ligands crossli ...... -4 and delta-opioid receptors.
@nl
type
label
Heterobivalent ligands crossli ...... -4 and delta-opioid receptors.
@en
Heterobivalent ligands crossli ...... -4 and delta-opioid receptors.
@nl
prefLabel
Heterobivalent ligands crossli ...... -4 and delta-opioid receptors.
@en
Heterobivalent ligands crossli ...... -4 and delta-opioid receptors.
@nl
P2093
P2860
P356
P1476
Heterobivalent ligands crossli ...... -4 and delta-opioid receptors.
@en
P2093
David L Morse
Eugene A Mash
Heather L Handl
Josef Vagner
Victor J Hruby
P2860
P304
P356
10.1002/ANIE.200702770
P407
P577
2008-01-01T00:00:00Z